ArisGlobal Announces Enhanced Global Trial Disclosure and Compliance Solution
“Clinical trial transparency is an established expectation today and this is being reinforced by regulation in many parts of the world,” commented Mathias Poensgen, product manager at ArisGlobal. “There are many registries and each requires differing data sets with unique business rules based on local regulation. Until standardization is achieved, the entire disclosure process will remain complex. With agDisclosure, sponsors can manage all disclosure activity from a single platform, reusing data sets multiple times while reports, metrics and dashboards give users insight into the worldwide status of their registries.”
agDisclosure is fully 21 CFR Part 11 compliant and provides built-in support for multiple trial registries, including ClinicalTrials.gov and EudraCT. Users can generate and review datasets, run validation checks, and create submission-ready XML files for upload. Key features include:
· Out-of-the-box validation rules.
· Flexible database structure with business rules adaptable to future registry requirements and new fields added without coding efforts.
· Import of data from any CTMS, including ArisGlobal’s agClinical™.
Configurable workflow capabilities support the data review and approval process required for submission while allowing multiple review cycles from different reviewers. Once approved, applicable submission sets can be created with appropriate registry-specific validations applied to ensure the integrity of the submission process. Necessary trial updates can also be submitted to the respective trial registry.
agDisclosure 3.1 is available to customers as a licensed, on-premise solution or as a hosted solution via agOnDemand™, ArisGlobal's highly proven Software-as-a-Service (SaaS) delivery platform.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025